Fundraising FoxFannin Goldenrod Holdings — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Procyrion develops medical devices for circulatory support in heart failure treatment, supported by a team of cardiologists and medical device industry veterans.
BiotechHealthtechMedical DevicesHouston, US
Reynolds, III M. Delagado(Director)Benjamin A. Hertzog(Executive Officer, Director)Dr. Fain(Founder/Executive)Jason J Heuring(Executive Officer)Bryan E. Nearn(Vice President)
BoardLeo III E Linbeck(Director)
Board seatLeo E Linbeck, III· per SEC Form D · $64M raise · filed Feb 2024
Co-investorsBluebird VenturesScientific Health DevelopmentTexas Ventures
Pulmotect develops immunomodulatory inhaled therapies designed to activate the lungs' innate immune system for preventing and treating respiratory complications in immunosuppressed patients and other high-risk populations.
BiotechHealthtechMedical DevicesHouston, US
Colin Broom(Executive Officer, Director)in
BoardKumar Srinivasan(Director)Atul Varadhachary(Director)Brenton Scott(President and Chief Operating Officer, Co-founder)Mark Worscheh(Director)in
Board seatLeo E. LinbeckLeo E. Linbeck IIILeo Linbeck III· per SEC Form D · filed Sep 2024
Co-investorsTexas Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.